55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Risk of microvascular complications over 30 years in latent autoimmune diabetes of adults compared with type 2 diabetes
E. Maddaloni, R.L. Coleman, O.F. Agbaje, R. Buzzetti, R.R. Holman
Diabetologia 2019;62:(Supp 1):S115 [Abstract]
2018
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin The effect of lixisenatide on post-prandial blood glucose and glucagon in type 1 diabetes
C. Ballav, A. Dhere, O. Agbaje, I. Kennedy, R.R. Holman, K.R. Owen
Diabetelogia 2018;61:(Suppl 1):S387 [Abstract]
2017
Diabetes UK Annual Professional Conference, Manchester Sensing hypoglycaemia at an earlier stage using an integrated physiological multi-signal data fusion approach
MJ Theodorakis, D Clifton, GW Colopy, J Jorge, A Dhere, C Ballav, I Kennedy, O Agbaje, L Tarassenko, RR Holman
Diabetic Medicine 2017;34 (Suppl 1):62-63 [Abstract]
Diabetes UK Annual Professional Conference, Manchester Estimating the potential incremental benefits on Type 2 diabetes complications rates of targeting successively lower LDL-cholesterol levels
SA Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman and MA Bethel
Diabetic Medicine 2017;34 (Suppl 1):36-194 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
O.F. Agbaje, R.L. Coleman, A.T. Hattersley, E.Z. Pearson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S300 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Modelling incremental benefits on macro- and micro-vascular complications rates when targeting lower systolic blood pressure levels in type 2 diabetes
S.A. Mostafa, R.L. Coleman, O.F. Agbaje, A. Gray, R.R. Holman, M.A. Bethel
Diabetelogia 2017;60:(Suppl 1):S525 [Abstract]
2016
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Estimated 10-year benefit for diabetes complication rates by 1% HbA1c decrements in people with type 2 diabetes and cardiovascular disease
S.A. Mostafa, R.R. Holman, R.L. Coleman, O. Agbaje, M.A. Bethel
Diabetologia 2016;59:Suppl 1:S543 [Abstract]
Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ
Tel: +44 (0)1865 857240 Email: dtu@dtu.ox.ac.uk
